Correction to Sanofi and Regeneron Pharmaceuticals Article on Sept. 28
September 30 2022 - 2:11PM
Dow Jones News
Sanofi and Regeneron Pharmaceuticals Inc. said there are about
75,000 adults in the U.S. living with prurigo nodularis who are
most in need of a new treatment option. "Sanofi, Regeneron Say
Dupixent Gets FDA Approval to Treat Prurigo Nodularis Skin
Disease," at 6:35 p.m. ET Sept. 28, incorrectly said the companies
said there are about 75,000 adults in the U.S. living with prurigo
nodularis.
(END) Dow Jones Newswires
September 30, 2022 14:56 ET (18:56 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024